InvestorsHub on MSN
Allogene publishes promising ALLO-329 data in Nature Communications
Allogene Therapeutics (NASDAQ:ALLO) said new pre-clinical data for its investigational CAR-T therapy ALLO-329 have been ...
The dosing of these two patients demonstrates Cellares’ GMP manufacturing and supply chain capabilities with their automated platform.
AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic CAR-T cell therapies, today announced that it has dosed the first patient ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...
Tandem CD19/CD22 chimeric antigen receptor T-cell therapy (CAR T-cell therapy) uses a single construct engineered to recognise both CD19 and CD22 on malignant B cells. This dual-targeting approach is ...
Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...
Post hoc analyses of pivotal MITIGATE trial show broad efficacy across patient subgroups with differing organ involvement and clinical characteristics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results